Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Prochowska, Ewa
JS001-027-III-HCC, NCT04523493 / 2020-004437-20: Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC	Active, not recruiting	3	530	Europe, RoW	Toripalimab combined with Lenvatinib, Placebo combined with Lenvatinib	Shanghai Junshi Bioscience Co., Ltd., Shanghai Junshi Biosciences Co., Ltd	Advanced Hepatocellular Carcinoma (HCC)	05/25	09/26
Wierzchosławska, Ewa
JS001-027-III-HCC, NCT04523493 / 2020-004437-20: Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC	Active, not recruiting	3	530	Europe, RoW	Toripalimab combined with Lenvatinib, Placebo combined with Lenvatinib	Shanghai Junshi Bioscience Co., Ltd., Shanghai Junshi Biosciences Co., Ltd	Advanced Hepatocellular Carcinoma (HCC)	05/25	09/26
Zybała, Patryk
JS001-027-III-HCC, NCT04523493 / 2020-004437-20: Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC	Active, not recruiting	3	530	Europe, RoW	Toripalimab combined with Lenvatinib, Placebo combined with Lenvatinib	Shanghai Junshi Bioscience Co., Ltd., Shanghai Junshi Biosciences Co., Ltd	Advanced Hepatocellular Carcinoma (HCC)	05/25	09/26